Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2022 | Next generation sequencing in breast cancer

Maria Fernanda Mosele • 5 May 2022
ESMO Breast 2022
Breast Cancer

Maria Fernanda Mosele, MD, Gustave Roussy, Villejuif, France, talks on the advantages of next generation sequencing (NGS) for accessing new treatments. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.

More from Maria Fernanda Mosele

Biological behaviour of HER2-low BC is dependent on HR expression
0:46
Biological behaviour of HER2-low BC is dependent on HR expression
Maria Fernanda Mosele • 5 May 2022
The significance of HER2 expression for the activity of trastuzumab deruxtecan
0:59
The significance of HER2 expression for the activity of trastuzumab deruxtecan
Maria Fernanda Mosele • 5 May 2022

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals